A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil
NCT05626088
Colitis, Colitis, Ulcerative
Santo André, São Paulo, Brazil
View Trial DetailsNCT Number: NCT01104753
Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hospital Brandýs n/Lab., Brandýs nad Labem, Czechia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Ferring Pharmaceuticals
Industry
Non-interventional Post Marketing Safety Study Confirming Efficacy and Safety of Pentasa Slow Release Tablets in Patients With Ulcerative Colitis in Common Clinical Practice
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05626088
Colitis, Colitis, Ulcerative
Santo André, São Paulo, Brazil
View Trial DetailsNCT04060303
Colitis, Colitis, Ulcerative
Chicago, Illinois, United States
View Trial DetailsNCT03847467
Colitis, Colitis, Ulcerative
Hartford, Connecticut, United States
View Trial DetailsNCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial Details